Cerliponase alfa ▼ is not registered in all countries, and where it is registered the content of its indication along with other content may vary.
Please refer to your local prescribing information before prescribing cerliponase alfa.
▼ This medicinal product is subject to additional monitoring, special reporting is required in relation to adverse reactions. Email us at medinfo@bmrn.com for further details.
This global initiative connects specialists, treatment centres, and referral networks together to optimise long term care for patients with NCLs.
Our mission is to share best practices, align care standards, and optimise patient pathways while fostering thought leadership and advancing rare disease education and care.
Through a series of interactive forums, educational resources, and expert-led webinars, LYNK provides a space to:
– Collaborate with peers and treatment centres to harmonise standards of care
– Share clinical experiences, challenges and evolving best practice
– Learn from real-world multidisciplinary perspectives
– Advance long-term outcomes for children living with NCLs
Together, we can build stronger connections, improve patient pathways and support optimal outcomes for patients with NCL worldwide.
Download or watch the latest from the LYNK Network
Video
Prof Angela Schulz, Steering Committee Chair, welcomes you to LYNK: the Lysosomal and NCL Insights and Knowledge-sharing Network. This is a global initiative to connect specialists, treatment centres and referral networks to optimise long-term care for patients with CLN2.
On Demand
Welcome to this inaugural LYNK webinar with Professor Angela Schulz and an esteemed global faculty to discuss transitioning patients with CLN2 disease from paediatric to adolescent care, with practical guidance on meeting the evolving needs of patients and working effectively with caregivers and care teams to navigate the process.